OTTAWA, June 01, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has made its first sale of Vivamune Health Chews into the Chinese market through an arrangement with Pawllion Inc.
China is the third largest pet market in the world with a growth rate of over 20% for 2017 and presents an enormous opportunity for Avivagen and its Vivamune Health Chews product. While Pawllion anticipates registration in China to take between 12-14 months, the company is permitted to distribute Vivamune Health Chews during this process and 1200 units have been provided to Pawllion to test the Chinese market with its distribution network. The agreement will include both mainland China and Hong Kong, and Pawllion will be featuring Vivamune Health Chews at PET FAIR ASIA, the largest pet exhibition in Asia, from August 22 nd -26 th , 2018.
“Avivagen’s goal for 2018 is to expand access to its products via approvals in new territories, signing distribution, partnering and licensing deals, all with the goal of helping sales of Avivagen’s products to grow,” stated Chairman and Interim CEO, Kym Anthony. Mr. Anthony further added, “This is our primary focus and we will continue to update our shareholders as we gain new approvals and sales in new territories.”
Pawllion Inc. ( www.pawllion.com ) is a U.S. registered company in California, specializing in wholesale and distribution of pet products internationally. Pawllion’s goal is to be a one-stop-shop for businesses looking to export specialty pet products globally. Unlike other shipping companies, Pawllion allows businesses to ship their products to their warehouse in California, with their team handling the international shipping process, including support for customs, clearing and registration if necessary.
About Avivagen Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .
About Vivamune™ Health Chews (Vivamune) Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com .
About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology arises from Avivagen’s discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors. Specifically, Avivagen has discovered the naturally occurring compound that is the actual source of β-carotene’s non-vitamin A activity and uses the synthetic version of the compound as the source of activity of Avivagen’s OxC-beta™ products. Importantly, the OxC-beta™ compound is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the size of the potential opportunity for Avivagen Inc.’s products in China, the process and timing for seeking regulatory approvals, the possibility of receiving such approvals, the activities of Pawllion and the possible outcomes of those activities, Avivagen Inc.’s goals for 2018 and the possibility for registration in mainland China and Hong Kong, approvals in new territories and signing distribution, partnering and licensing deals to increase Avivagen Inc.’s sales are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen may not gain market acceptance or regulatory approval in mainland China and Hong Kong in the time frame anticipated or at all and, if regulatory approval is granted, it may not have the anticipated effects on Avivagen Inc.’s sales due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information: Avivagen Inc. Drew Basek Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail: d.basek@avivagen.com
Kym Anthony Chairman & Interim CEO 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website: www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
